• Français

Centre de recherche
Monday, October 26 2015
Press release

20% of kids don't respond to standard cancer treatment. Now there is new hope.

World first clinical study launched in patients facing a therapeutic dead end launched at CHU Sainte-Justine

MONTRÉAL, October 26, 2015 – A new drug combination being trialled in a groundbreaking CHU Sainte-Justine/University of Montreal study at is giving hope for survival, healing and improved quality of life to the 20% of children who do not respond to standard cancer treatments. Known as DEC-GEN, it’s the world’s first study involving children with solid tumors or recurrent or refractory leukemia. It was designed at the CHU Sainte-Justine Research Centre by principal investigators Dr. Noël Raynal and Dr. Henrique Bittencourt, both professors at the University of Montreal, and aims to evaluate the effectiveness, in children, of a combination of two drugs, decitabine and genistein, which are already used individually in the treatment of cancers. This drug combination therapy developed at the Institut national de la recherche scientifique (INRS).

Funded by Gateway for Cancer Research and the in-kind contribution of Pharmascience and DSM Nutritional Products, who will be providing decitabine and genistein respectively at no charge for the duration of the study, the DEC-GEN study is being carried out in collaboration with the INRS. It’s innovative approach lies in the epigenetic action created by combining two drugs, namely decitabine, used to treat acute leukemias, and genistein, a natural isoflavone found in soybeans. The two molecules act synergistically to reprogram cancer cells and stop their progression, specifically targeting epigenetic alterations such as DNA hypermethylation, responsible for repressing tumor suppressor genes.

"The DEC-GEN combination is significantly less toxic than conventional therapies, because the effective dose is minimized through the synergetic action of the two molecules," says Noël Raynal, drawing upon the preliminary results of a clinical trial that was conducted with patients with solid tumors at the Notre-Dame Hospital of the CHUM. This trial was undertaken on behalf of the INRS and with the close collaboration of Pharmascience and DSM Nutritional Products.

 

Phase I of the study will be conducted in the first year at CHU Sainte Justine with 12 patients aged 2 to 20 years who are facing a therapeutic dead end. The objective is to assess the impact of a dose-escalated treatment on biological factors, such as DNA methylation, and on pharmacokinetic and pharmacogenetic parameters. Once the optimal dose is identified, phase II of the study will be extended to other pediatric oncology centers in Canada. In total, the researchers aim to treat 24 patients in the course of this study.

 

In addition to achieving the obvious sought and expected clinical benefits for patients, the researchers are confident that their work will broaden the horizon of scientists in their quest for other combinations of epigenetic drugs to fight cancers.

 

– 30 –

About the CHU Sainte-Justine Research Center

CHU Sainte-Justine Research Center is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 200 research investigators, including over 90 clinician-scientists, as well as 360 graduate and postgraduate students focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine. The Center is part of CHU Sainte-Justine, which is the largest mother-child center in Canada and second most important pediatric center in North America. More on research.chusj.org

Source
CHU Sainte-Justine
Contact

Marise Daigle, communications, Communications, CHU Sainte-Justine Research Center
marise.daigle@recherche-ste-justine.qc.ca

About the researchers

Dr. Noël Raynal, is a principal investigator at CHU Sainte-Justine and assistant professor in the Department of Pharmacology at Université de Montréal. Dr. Henrique Bittencourt is a hemato-oncologist and a researcher at CHU Sainte-Justine, and an assistant clinical professor in the Department of Pediatrics at Université de Montréal.

About the study

People interested in the study may contact the research team to learn more.

Information
Anne-Julie Landry, Project Lead
Hematology, Oncology and Immunology Research Unit
CHU Sainte-Justine
514 345-4931, extension 6471
anne-julie.landry@recherche-ste-justine.qc.ca

About this page
Updated on 10/26/2015
Created on 10/23/2015
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine